Company news
Spero Therapeutics, Inc. (NASDAQ:SPRO) news
Spero Therapeutics, Inc. news releases on 6ix. Latest, Mar 5, 2020: Spero Therapeutics Announces Closing of Rights Offering
Press releases — page 3
Spero Therapeutics Announces Closing of Rights Offering
March 4, 2020
Spero Therapeutics Announces Commencement of Rights Offering
February 10, 2020
Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
February 4, 2020
Spero Therapeutics Announces Proposed Rights Offering
January 29, 2020
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
January 12, 2020
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease
December 3, 2019
Spero Therapeutics to Host Key Opinion Leader Symposium in December
November 25, 2019
Spero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review
November 3, 2019
Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial
October 2, 2019
Spero Therapeutics Announces Presentations at IDWeek 2019
September 25, 2019